Fundraising FoxBiotech Startups
11,136 companies tagged Biotech, with their investors and founders.
Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
0 investors
0 investors
0 investors
Vaginal Biome Science (VBS) is a biotechnology and R&D company developing microbiome-based diagnostics, therapeutics, and consumer care products for vaginal health, using its patented BioMatch technology and clinical research such as the VENUS Study. It serves the women's health market with clinically validated products and microbiome measurement tools.
0 investors
Vala Sciences develops high-content kinetic screening technologies, including imaging instruments, analysis software, and AI tools, to extract single-cell insights for drug discovery, disease modeling, and therapeutic research. It also provides contract research services such as cardiac safety screening, neuroscience applications, and high-content analysis for preclinical researchers.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Vascudyne develops allograft tissue engineered from biological materials for regenerative medical applications, including heart valve therapies. The company advances non-immunogenic tissue solutions for clinical use.
0 investors
Vascular Perfusion Solutions develops the VP.S ENCORE, a portable cardiac perfusion system using a blood-free perfusate to extend donor heart viability up to 8 hours for transplant recovery teams. The investigational medical device is in preclinical evaluation under FDA Breakthrough Device Designation.
0 investors
Vascular Pharmaceuticals develops VPI-2960B, a therapeutic candidate in clinical development for diabetic nephropathy treatment. The company focuses on advancing this potential breakthrough therapy through Phase 2 trials.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors